Effects of the Connections program on return‐to‐custody, mortality and treatment uptake among people with a history of opioid use: Retrospective cohort study in an Australian prison system
Addiction · 2024
DOI: 10.1111/add.16339 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Addiction, 2024. Verfasst von Elizabeth Sullivan und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW, Australia. Hauptthemen laut MEDLINE: Opioid-Related Disorders, Prisoners. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.
Abstract (Originalsprache)
Background and Aims Connections is a voluntary health program that facilitates access to opioid agonist treatment (OAT) and social services for people with opioid use exiting prison. This study aimed to measure the effectiveness of Connections in reducing recidivism and improving health outcomes for people with a history of opioid use on leaving prison.
Design
Retrospective cohort study with quasi‐random allocation to the program.
Setting
Public adult prisons in New South Wales, Australia, 2008–2015.
Participants
Adults released from custody with a history of opioid use. Of 5549 eligible releasees, 3973 were allocated to Connections and 1576 to treatment‐as‐usual.
Measurements
Outcomes were return‐to‐custody, all‐cause mortality, and OAT participation.
Findings
Regression analyses on an intention‐to‐treat basis, and adjusting for baseline propensity scores, comparing patients allocated to Connections versus treatment‐as‐usual showed no difference in rates of return‐to‐custody within 2 years (hazard ratio [HR]: 1.01; 95% confidence interval [CI]: 0.92 –1.12). Patients allocated to the Connections program were more likely to access OAT (odds ratio [OR]: 1.21; 95% CI: 1.06–1.39) and had lower mortality within 28 days of release (0.25% vs. 0.66%; HR: 0.38; 95% CI: 0.14–1.03). Differences in mortality did not persist beyond 28 days. Subgroup analyses showed that allocation to Connections was associated with higher risk of return‐to‐custody within 28 days for Aboriginal and/or Torres Strait Islander (Indigenous) and female releasees.
Conclusions
The Connections program for people with opioid use exiting prison did not reduce the likelihood of return‐to‐custody but did facilitate opioid agonist treatment participation on release from prison.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW, Australia.
- Justice Health and Forensic Mental Health Network, Malabar, NSW, Australia.
- University of Technology Sydney, Ultimo, NSW, Australia.
ORCID-Profile: Elizabeth Sullivan, Stephen Ward, Kypros Kypri
Förderung
- National Health and Medical Research Council
Zitieren
APA
Sullivan, E., Zeki, R., Ward, S., Sherwood, J., Remond, M., Chang, S., Kypri, K., & Brown, J. (2024). Effects of the Connections program on return‐to‐custody, mortality and treatment uptake among people with a history of opioid use: Retrospective cohort study in an Australian prison system. Addiction. https://doi.org/10.1111/add.16339
Vancouver
Sullivan E, Zeki R, Ward S, Sherwood J, Remond M, Chang S, et al. Effects of the Connections program on return‐to‐custody, mortality and treatment uptake among people with a history of opioid use: Retrospective cohort study in an Australian prison system. Addiction. 2024. doi:10.1111/add.16339
BibTeX
@article{Sullivan2024,
author = {Sullivan, Elizabeth and Zeki, Reem and Ward, Stephen and Sherwood, Juanita and Remond, Marc and Chang, Sungwon and Kypri, Kypros and Brown, James},
title = {Effects of the Connections program on return‐to‐custody, mortality and treatment uptake among people with a history of opioid use: Retrospective cohort study in an Australian prison system},
journal = {Addiction},
year = {2024},
doi = {10.1111/add.16339}
}
EUVIMED